Drug intelligence / Profile preview

W2505-R

Development stage: Unknown
Lead developer: GL Pharm Tech
Modality: Small Molecules
Administration: Oral

Overview

W2505-R is an active comparator drug code used in a Phase 3 clinical trial (study W2505-301) sponsored by GL Pharm Tech Corporation, evaluating treatments for erectile dysfunction in adult males. Within the trial, W2505-R serves as the active comparator arm (paired with W2505-P1 as a placebo for the investigational drug W2505) and is administered orally once daily for 12 weeks. The exact active ingredient, biological target, and modality of W2505-R have not been publicly disclosed under this specific designation.

Beyond the preview

Go deeper on W2505-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on W2505-R.